Nkarta (NKTX) Asset Writedowns and Impairment (2023 - 2025)
Nkarta's quarterly Asset Writedowns and Impairment came in at $791000.0 in Q3 2025, up 1.698659565567999e+17% quarter-over-quarter from $0.0 in Q4 2023.
Nkarta has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $791000.0 in Q3 2025.
- For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $791000.0; the trailing twelve-month figure through Dec 2025 stood at $791000.0 (up 1.698659565567999e+17% YoY), and the FY2025 full-year result was $791000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $791000.0, up from $0.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $4.1 million in Q2 2023, with the low at $0.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 791,000.00 |
| Sep 30, 2025 | 791,000.00 |
| Dec 31, 2023 | 0.00 |
| Dec 31, 2023 | 0.00 |
| Jun 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 4.10 Mn |